This is in marked contrast to NSCLC, particularly adenocarcinoma, where genome sequencing efforts have revealed the identity of numerous recurrent, actionable somatic alterations, including oncogenic EGFR mutations, as well as ALK- and ROS1 rearrangements46. The gene discussed is EGFR; the disease is adenocarcinoma.